OLD National Bancorp IN Has $269,000 Stake in Insulet Co. (NASDAQ:PODD)

OLD National Bancorp IN decreased its position in Insulet Co. (NASDAQ:PODD) by 16.2% during the 4th quarter, HoldingsChannel reports. The fund owned 1,239 shares of the medical instruments supplier’s stock after selling 240 shares during the quarter. OLD National Bancorp IN’s holdings in Insulet were worth $269,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in PODD. Parkside Financial Bank & Trust grew its stake in shares of Insulet by 251.0% during the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 123 shares in the last quarter. Allworth Financial LP grew its stake in shares of Insulet by 104.5% in the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 92 shares in the last quarter. Wolff Wiese Magana LLC grew its stake in shares of Insulet by 2,680.0% in the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 134 shares in the last quarter. BluePath Capital Management LLC bought a new position in shares of Insulet in the third quarter valued at $31,000. Finally, Lindbrook Capital LLC grew its stake in shares of Insulet by 64.1% in the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after buying an additional 75 shares in the last quarter.

Insider Buying and Selling

In related news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the sale, the director now owns 2,567 shares of the company’s stock, valued at approximately $418,215.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

PODD has been the topic of several recent analyst reports. Stifel Nicolaus boosted their price target on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research note on Monday, February 5th. Barclays dropped their price target on Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research note on Monday, February 26th. Piper Sandler dropped their price target on Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research note on Friday, February 23rd. Finally, JPMorgan Chase & Co. upped their target price on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Insulet has an average rating of “Moderate Buy” and an average price target of $243.21.

Insulet Stock Down 1.8 %

PODD stock opened at $164.17 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. The company has a market capitalization of $11.50 billion, a price-to-earnings ratio of 56.42, a PEG ratio of 3.01 and a beta of 0.98. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $335.91. The stock has a fifty day moving average of $172.00 and a 200-day moving average of $179.25.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.73. The company had revenue of $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The firm’s quarterly revenue was up 37.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.55 EPS. As a group, equities research analysts predict that Insulet Co. will post 3.08 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.